

0946543-084304




Fig 1

0929513.001304




Fig. 2

FIG. 3

300




FIG. 3

09425513 081301





Fig 4 A

FIG. 4B




Fig 4B

TOP SECRET




Fig 5




Fig 6

0920513.081301
T0180 ET 562550




Fig 7




Fig 8A





FIG. 8B

MCS: RF and Microwave



▪ Detects protein "soft vibrations"

▪ Protein Motions $10 \text{ psec} - 100 \text{ nsec}$



▪ Complexation of Solvent

▪ Water, ions, cofactors, small molecules, other proteins





Integration of the Biology

- Biological systems as dielectric circuit element
- Integration into circuit configurations



Permittivity vs. Structure: Fibrinogen Digest


Digestion of Fibrinogen with Crude Protease



TOEYBO" ET552660


Tyrosine kinase assay

.132 units/ul c-src, 200 uM (.3 mg/ml) substrate (521) and 150 uM ATP



MCS broadband signatures

Differ between proteins



Value Proposition


- Permittivity → Function
- No Engineering → Direct and Rapid Access



TOETED" ET552550

MCS in Drug Discovery:


A Parallel Approach



MCS: solving discovery problems



- "Target-fishing"
 - we can detect proteins in solution
 - we can classify unknown protein targets
 - we can de-orphan unknown protein targets
- Quantifying binding
- Qualifying leads using protein/ligand classification with MCS
- SAR using MCS
- Cellular assays with MCS

MCS in Drug Discovery




- Quantified binding measurements
- Label-free assays
- Rapid assay prototyping and development
- Physiologically relevant conditions
- Medium throughput
- Molecular system

Similar proteins have similar signatures Change in permittivity at 1.3 GHz




TDETB0" ETS62660




MCS cellular response to ionomycin

CHOWt




CHO-transfected




Thapsigargin

S21 Pt M1 Treated With Iono and Thaps




~~SECRET~~

% Activation S21 Pt M1 Cells Ionomycin and Thaps




Multiple Discrete Frequency Analysis


Change in E' and E'' at 1.3 GHz




Change in E' and E'' at 3.9 GHz





Change in E' and E'' at 2.6 GHz



Change in E' and E'' at 5.2 GHz



Tertiary structural homology prediction




Signature
BioScience, Inc.

Clustering for protein function

Form1

Clustered Samples



☒ Show Clusters ☐ Show Grids

Exit

CurveID : 221
 NumPoints : 0
 AveragingFactor : 0
 SourcePower : 0
 IFFBandwidth : 0
 SmoothingFactor : 0
 StartFrequency : 0
 StopFrequency : 0
 CenterFrequency : 0
 FrequencySpan : 0
 BoxTemperature : 0
 SampleTemperature : 0
 ResonatorTemperature : 0
 AmbientTemperature : 0
 center_J : 5.17505100147065E-04
 center_Q : -8.5745278068338E-04
 center_rotQ : 1.00148678203395E-03
 center_rotI : 7.81163813038638E-06
 center_reZD : 1.00200498142419
 center_limZD : 1.56547365823356E-05
 center_freq : 1.29978140933176
 DeltaFreq : -1.80340688048819E-07
 DeltaReZ : 2.71464140071287E-04
 DeltaImZ : 3.81470843616835E-06
 FittedCenterFreq : null
 MinimumMagnitude : null
 NormalizedQuality : null
 delta_resistance : 6.34500655598114E-04
 delta_reactance : 1.56547365823356E-05
 delta_epsilon_p : null
 delta_epsilon_pp : null
 seqid : 9


(hypothetical)

Or, de-orphaning using annotated compound libraries...


Calibrate
Signal



Read annotated
ligand interactions with
Unknown protein




Use annotated hits to
develop hit/no hit database



....Enabling clustering for compound effect

(hypothetical)



Non-competitive binding assays


- Methods to detect weak binders are slow
 - Competitive assays usually won't work
- "Orphan-like" targets may have no affinity ligand
- Allosteric binders difficult to find
- Label artifacts
- Bioconjugation

IL-2/IL-2R Inhibitors

IL-2 is the principle cytokine involved in cell-mediated immunity.

Antibodies against IL-2R α approved for graft rejection.

- Well-characterized small-molecule inhibitors of IL-2 have been discovered



$IC_{50} = 3 \mu M$




SUNESIS

Roche Research Center (Nutley)

J.W. Tilley, et al. JACS (1997) 119, 7589-7590.


MCS analysis of binding to IL-2, IL-4



MCS binding results same as others


Method	IC ₅₀ /K _d
SPA	3 μM
MCS	4 μM
AUC	5 μM
SPR	20 μM
ITC	4 μM

SPA – scintillation proximity assay
MCS – multipole coupling spectroscopy
AUC – analytical ultracentrifugation
SPR – surface plasmon resonance
ITC – isothermal calorimetry



MCS in Drug Discovery

Drug Discovery Process




Ligand function classification

- "Bin" hits
 - agonists would cause similar responses to each other
 - distinct responses from antagonists
- Nuclear Receptor-based
 - "binning" of hits
 - quantify relationships to known compounds
 - e.g. Ligand-1 like or Ligand-2 like

Lack of a functional readout is a problem


- No ready, quick method for categorizing the effect a "hit" chemical has on a given target, when certain profiles are desired (ie, a functional, but not chemical, copy)
- Clear desire for a fast means of "target-fishing" using annotated compound libraries and other techniques

MCS of NR – L1 interaction at 1.3 GHz




NR/ligand interaction comparison

Normalised Response (ligand 1 & 2)



...Enabling clustering for ligand function *(hypothetical)*

Form1




Structure/activity using MCS ?

- The opportunity:
 - Perform X-ray crystallography or NMR routinely
 - Earlier in the discovery process
- The problem:
 - Cost, reagents required, technology repertoire limitations, and time-consuming nature of the processes involved, are prohibitive

Protein Function: Estrogen receptor-ligand interaction

- X-ray analysis has shown that DES (agonist) and Tamoxifen (antagonist) cause subtly different conformation changes to ER on binding interaction



POSTED: 01/26/2000

MCS signatures correlate interaction data


SAR Data from ER
Model System

SAR with MCS – x-ray in advance


Obtaining predicted structural readouts, enabled by “wet-lab” MCS data, and augmented by unique software...

- Jump starts SAR, typically undertaken later

...Enabling clustering for ligand function *(hypothetical)*



MCS in Drug Discovery



MCS: solving discovery problems

- "Target-fishing"
 - we can detect proteins in solution
 - we can classify unknown protein targets
 - we can de-orphan unknown protein targets
- Quantifying binding
- Qualifying leads using protein/ligand classification with MCS
- SAR using MCS
- Cellular assays with MCS

Cellular MCS: Overview

- Protein structure→cell organization
- Many physiologic processes can be measured
 - GPCR-mediated pathway induction
 - Ion channel modulation
 - Morphologic changes
 - Apoptotic events

Cellular MCS

- Protein Structure → Cellular Organisation
- MCS Measures Physiologic Changes in Cells
 - Ion Flux
 - Cytosolic cAMP/Ca²⁺
 - Morphologic Changes
 - Membrane changes

Specificity in MCS Cellular Analyses


- Spectral Response
- Kinetics
- "Orthogonal" properties
 - Protein expression levels
 - Focused libraries
- Diverse cell populations

MCS hits major screening bottlenecks...

- Target ID, validation, *access* ✓
- Rapid Assay Development ✓
- Secondary Screening and Lead Optimization ✓
- Data Management and Analysis ✓


...and MCS meets defined “drivers” for new detection technologies

- Simple one step homogeneous assay ✓
- Avoid radioactivity, safety, disposal costs ✓
- Sensitivity to replace radioactivity ✓
- Reagent, target and compound sparing ✓
- Speed / throughput ✓
- Higher quality information ✓




A GPCR-mediated pathway:

Activation of muscarinic m₁ receptor



Ca Flux 2° Assay on LJL Analyst




CPW

- 50MHz – 1GHz
- 101 points, -10 dBm
- IF Bandwidth – 10Hz
- SP11 & SP21
- Au & Pt chips
- 5×10^4 cells/well plated the day before
- Vivian's New Sucrose Buffer


TOCTBO ET562660

M1 Cells on .505 Pt CPW




MCS cellular response

- CHO cells – wild type and transfected with well-known GPCR (Gq-coupled)
- Agonist stimulation is seen in transfected cells, not in WT cells
- 2ndary assay: Calcium flux measured in L3L Analyst




MCS cellular response

- Same cell lines as previous slide
- Agonist stimulation is blocked by pre-treatment with 1 μ M antagonist





Time course of response to agonist



Dose-Response Curves:


CHO-K1 vs. CHO-M1: carbachol



10/01/2000 15:22:50

PZP Dose curves ... MCS & Ca²⁺ Flux


CHO_{M1} cells treated with 300 nM Carbachol +/- Pirenzepine



TOE180" ET562650

300 nM Carb + PZP

CHO_{M1} cells treated with 300 nM Carbachol +/- Pirenzepine



M1 – 300 nM Carb vs PZP





Doses

Conclusions:

- PZP always blocks activation by 300 nM Carbachol
- Dose of PZP required to block Carb response varies everyday (look at 3 nM, 10 nM)
- Range of positive response can vary a lot


CHO₄₁ cells treated with 300 nM Carbachol +/- Pirenzepine

TOGETHER WITH CHO₄₁ cells treated with 300 nM Carbachol +/- Pirenzepine




Roger Plot...


CHO_{K1} cells treated with 300 nM Carbachol +/- Pirenzepine




CHO_{K1} cells treated with 300 nM Carbachol +/- Pirenzepine



CHO_{K1} cells treated with 300 nM Carbachol +/- Pirenzepine



CHO_{K1} cells treated with 300 nM Carbachol +/- Pirenzepine (7-11)



Dose-Response vs. Inhibitor (Telenzepine)

